US4708964A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lipoxygenase inhibitors
Assignee: BLOCK/CHEMEX GP A NEW JERSEY GENERAL PARTNERSHIP
•
Filing: 1984-02-09
•
Granted: 1987-11-24
•
Expires: 2004-02-09
Abstract
Abstract This invention provides methods of using a number of compounds for the inhibition of lipoxygenase in humans. Pathological conditions which may be treated by the compounds described herein include psoriasis, cellular proliferation, skin allergies, insect bites, allergic rhinitis, conjunctivitis, hay fever, bronchial asthma, allergic gastroenteritis, uterine contractions, hyperactivity of the colon and bronchospasms.
Inventors
- 👤 Larry M. Allen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 19:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/045; A61K31/05; A61K31/075; A61K31/085; A61K31/11; A61K31/185; A61K31/19; A61K31/20; A61K31/21; A61K31/215; A61K31/33; A61K31/335; A61K31/357; A61K31/36
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
258 words
The method for treating psoriatic lesions in a host in need of such treatment comprising topically applying to said lesions an effective amount of a pharmaceutical preparation comprising a suitable pharmaceutical carrier and a compound selected from the compound of the formulae: ##STR11## wherein R 1 is --OC) n (CH 2 ) m COOR and where n is 0 or 1, m is 1-4, and R is H, --CH 3 or --C 2 H 5 ; or an acid moiety, including an amino acid moiety; R 2 , R 3 and R 4 are, independently, H or R 1 ; and R 5 and R 6 are, independently, H or --CH 3 ; ##STR12## wherein R 1 , R 2 , R 3 and R 4 are, independently, H or --CH 3 ; or R 1 and R 2 and/or R 3 and R 4 taken together are --CH 2 --; R 5 and R 6 are, independently, H or --CH 3 ; and R 7 and R 8 are, independently, H, --SO 3 H or --SO 3 Na; and ##STR13## wherein there are, independently, double or single bonds in the 1-2 and 3-4 positions; and R 1 , R 2 , R 3 and R 4 are, independently, H, --CH 3 , or R 1 and R 2 and/or R 3 and R 4 taken together are --CH 2 --; and R 5 and R 6 are, independently, a 2-12 dienoic fatty acid moiety, a 1-12 mono- or dialkene, --CHO, --COOH or taken together are succinic anhydride.
Claim 2
Independent Claim
258 words
The method for treating psoriatic lesions in a host in need of such treatment comprising topically applying to said lesions an effective amount of a pharmaceutical preparation comprising a suitable pharmaceutical carrier and a compound selected from the compound of the formulae: ##STR11## wherein R 1 is --OC) n (CH 2 ) m COOR and where n is 0 or 1, m is 1-4, and R is H, --CH 3 or --C 2 H 5 ; or an acid moiety, including an amino acid moiety; R 2 , R 3 and R 4 are, independently, H or R 1 ; and R 5 and R 6 are, independently, H or --CH 3 ; ##STR12## wherein R 1 , R 2 , R 3 and R 4 are, independently, H or --CH 3 ; or R 1 and R 2 and/or R 3 and R 4 taken together are --CH 2 --; R 5 and R 6 are, independently, H or --CH 3 ; and R 7 and R 8 are, independently, H, --SO 3 H or --SO 3 Na; and ##STR13## wherein there are, independently, double or single bonds in the 1-2 and 3-4 positions; and R 1 , R 2 , R 3 and R 4 are, independently, H, --CH 3 , or R 1 and R 2 and/or R 3 and R 4 taken together are --CH 2 --; and R 5 and R 6 are, independently, a 2-12 dienoic fatty acid moiety, a 1-12 mono- or dialkene, --CHO, --COOH or taken together are succinic anhydride.
Claim 3
Dependent Claim
26 words
The method of claim 1 in which said pharmaceutical preparation also contains zinc chloride in an amount of between about 0.5 and about 30 weight percent.
Claim 4
Dependent Claim
21 words
The method of claim 1 wherein said compound is selected from the group consisting of 1-(3,4-di-ethoxy-carbonylmethoxyphenyl),4(3-hydroxy,4-ethoxycarbonylmethoxyphenyl,2,3-dimethylbutane; 1,4-bis(3-hydroxy,4-ethoxycarbonylmethoxyphenyl),2,3-dimethylbutane; and nordihydroguaiaretic acid tetra-O-ethylhemisuccinate.
Claim 5
Dependent Claim
12 words
The method of claim 3 wherein said compound is nordihydroguaiaretic acid tetra-O-ethylhemisuccinate.
Claim 6
Dependent Claim
10 words
The method of claim 3 wherein said compound is 1-(3,4-di-ethoxycarbonylmethoxyphenyl),4(3-hydroxy,4-ethoxycarbonylmethoxyphenyl),2,3-dimethylbutane.
Claim 7
Dependent Claim
10 words
The method of claim 3 wherein said compound is 1,4-bis(3-hydroxy,4-ethoxycarbonylmethoxyphenyl),2,3-dimethylbutane.
References Cited (Backward Citations)
US2984674A
Cited
US3054802A
Cited
US3634459A
Cited
US3524844A
Cited
US3408441A
Cited
US3502770A
Cited
US3896238A
Cited
US4294763A
Cited
US4391982A
Cited
US4358461A
Cited
US4451475A
Cited
US4442099A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-11-23 | 1991-05-25 | 1991-11-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-11-23 | 1995-05-25 | 1995-11-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-11-23 | 1999-05-25 | 1999-11-24 | $7700.00 | Window Closed / Lapsed |